Advanced Prostate Cancer: From the Editor

22 August 2024

For more than 20 years, UroToday has been THE premier online educational resource for genitourinary oncology – clinicians educating clinicians. During this time, advanced prostate cancer has been completely transformed, pa≥ particularly in the last 10+ years. Since then, we have seen (briefly) the following in advanced prostate cancer:

• Docetaxel for mCRPC progression
• Cabazitaxel following docetaxel for mCRPC progression
• Radium-223 for mCRPC
• Docetaxel + ADT for mHSPC
• Abiraterone + prednisone for mHSPC
• ARPIs + ADT for mHSPC
• ARPIs + ADT for M0 CRPC
• Enzalutamide +/- ADT for non-metastatic HSPC
• PARP inhibitors for mCRPC
• Radioligand therapy for mCRPC